"You have to have a certain healthy skepticism if you hear someone has drugged Ras."
Carlo Rizzuto, venture partner at Versant Ventures, which backed start-up Kyras Therapeutics Inc., on the difficulty of Ras as a drug target

"People start paying attention when you start giving them back money."
Antoine Papiernik, managing partner at Sofinnova, on why it bested the fundraising target in its recently closed €300 million fund

"That balance that we struck never anticipated companies acquiring off-patent drugs and then jacking up their prices to enormous heights, and doing so, as one executive put it, 'Because I can,' but that is exactly what we have seen in recent months."
Sen. Susan Collins (R-Maine), during the first of a series of hearings of the Senate Special Committee
on Aging, on efforts to balance innovation and profit

"If a drug is older than the founder of the company, there is no R&D."
Mark Merritt, president and CEO, Pharmaceutical Care Management Association, during the Senate Special Committee on Aging, taking a shot at Turing Pharmaceuticals Inc.'s founder, Martin Shkreli, whose firm acquired a 62-year-old drug and raised the price 5,500 percent